Paying users zone. Data is covered by .
Get to AbbVie Inc. for $19.99, or
get to entire website for at least 3 months from $49.99.







Analysis of Operating Leases
Difficulty: Advanced
An operating lease is treated like a rental contract. Neither the leased asset nor the associated liability is reported on the lessee statement of financial position, but the rights may be very similar to the rights of an owner. The lessee only records the lease payments as a rental expense in income statement.
- Present Value of Future Operating Lease Payments
- Analyst Adjustments for Operating Leases
- Adjusted Ratios for Operating Leases (Summary)
- Adjusted Total Asset Turnover
- Adjusted Debt to Equity
- Adjusted Return on Assets (ROA)
- Adjusted Interest Coverage
- Estimation of Depreciation Expense, Operating Leased Assets
- Estimation of Interest Expense, Operating Lease Obligations
- Present Value of Operating Lease Payments, at Beginning of Year
Present Value of Future Operating Lease Payments
AbbVie Inc., future operating lease payments
Based on: 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-20), 10-K (filing date: 2014-02-21).
1 Weighted-average interest rate for AbbVie Inc.’s debt
Year | Future operating lease payments (as reported) | Year | Future operating lease payments (estimated) | Present value at ![]() |
---|---|---|---|---|
2018 | ![]() |
2018 | ![]() |
![]() |
2019 | ![]() |
2019 | ![]() |
![]() |
2020 | ![]() |
2020 | ![]() |
![]() |
2021 | ![]() |
2021 | ![]() |
![]() |
2022 | ![]() |
2022 | ![]() |
![]() |
2023 and thereafter | ![]() |
2023 | ![]() |
![]() |
2024 | ![]() |
![]() |
||
2025 | ![]() |
![]() |
||
2026 | ![]() |
![]() |
||
2027 | ![]() |
![]() |
||
2028 | ![]() |
![]() |
||
2029 | ![]() |
![]() |
||
Total: | ![]() |
![]() |
![]() |
Based on: 10-K (filing date: 2018-02-16).
Year | Future operating lease payments (as reported) | Year | Future operating lease payments (estimated) | Present value at ![]() |
---|---|---|---|---|
2017 | ![]() |
2017 | ![]() |
![]() |
2018 | ![]() |
2018 | ![]() |
![]() |
2019 | ![]() |
2019 | ![]() |
![]() |
2020 | ![]() |
2020 | ![]() |
![]() |
2021 | ![]() |
2021 | ![]() |
![]() |
2022 and thereafter | ![]() |
2022 | ![]() |
![]() |
2023 | ![]() |
![]() |
||
2024 | ![]() |
![]() |
||
2025 | ![]() |
![]() |
||
2026 | ![]() |
![]() |
||
2027 | ![]() |
![]() |
||
Total: | ![]() |
![]() |
![]() |
Based on: 10-K (filing date: 2017-02-17).
Year | Future operating lease payments (as reported) | Year | Future operating lease payments (estimated) | Present value at ![]() |
---|---|---|---|---|
2016 | ![]() |
2016 | ![]() |
![]() |
2017 | ![]() |
2017 | ![]() |
![]() |
2018 | ![]() |
2018 | ![]() |
![]() |
2019 | ![]() |
2019 | ![]() |
![]() |
2020 | ![]() |
2020 | ![]() |
![]() |
2021 and thereafter | ![]() |
2021 | ![]() |
![]() |
2022 | ![]() |
![]() |
||
2023 | ![]() |
![]() |
||
2024 | ![]() |
![]() |
||
2025 | ![]() |
![]() |
||
2026 | ![]() |
![]() |
||
2027 | ![]() |
![]() |
||
Total: | ![]() |
![]() |
![]() |
Based on: 10-K (filing date: 2016-02-19).
Year | Future operating lease payments (as reported) | Year | Future operating lease payments (estimated) | Present value at ![]() |
---|---|---|---|---|
2015 | ![]() |
2015 | ![]() |
![]() |
2016 | ![]() |
2016 | ![]() |
![]() |
2017 | ![]() |
2017 | ![]() |
![]() |
2018 | ![]() |
2018 | ![]() |
![]() |
2019 | ![]() |
2019 | ![]() |
![]() |
2020 and thereafter | ![]() |
2020 | ![]() |
![]() |
2021 | ![]() |
![]() |
||
Total: | ![]() |
![]() |
![]() |
Based on: 10-K (filing date: 2015-02-20).
Year | Future operating lease payments (as reported) | Year | Future operating lease payments (estimated) | Present value at ![]() |
---|---|---|---|---|
2014 | ![]() |
2014 | ![]() |
![]() |
2015 | ![]() |
2015 | ![]() |
![]() |
2016 | ![]() |
2016 | ![]() |
![]() |
2017 | ![]() |
2017 | ![]() |
![]() |
2018 | ![]() |
2018 | ![]() |
![]() |
2019 and thereafter | ![]() |
2019 | ![]() |
![]() |
2020 | ![]() |
![]() |
||
2021 | ![]() |
![]() |
||
2022 | ![]() |
![]() |
||
2023 | ![]() |
![]() |
||
2024 | ![]() |
![]() |
||
2025 | ![]() |
![]() |
||
2026 | ![]() |
![]() |
||
2027 | ![]() |
![]() |
||
2028 | ![]() |
![]() |
||
2029 | ![]() |
![]() |
||
2030 | ![]() |
![]() |
||
Total: | ![]() |
![]() |
![]() |
Based on: 10-K (filing date: 2014-02-21).
Analyst Adjustments for Operating Leases
AbbVie Inc., adjustments to financial data
USD $ in millions
Based on: 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-20), 10-K (filing date: 2014-02-21).
1, 2 Equal to total present value of future operating lease payments. See Details »
AbbVie Inc., Financial Data: Reported vs. Adjusted
Adjusted Ratios for Operating Leases (Summary)
AbbVie Inc., adjusted ratios
Based on: 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-20), 10-K (filing date: 2014-02-21).
Ratio | Description | The company |
---|---|---|
Adjusted total asset turnover | An activity ratio calculated as total revenue divided by adjusted total assets. | AbbVie Inc.’s adjusted total asset turnover deteriorated from 2015 to 2016 but then slightly improved from 2016 to 2017. |
Adjusted debt-to-equity | A solvency ratio calculated as adjusted total debt divided by total shareholders’ equity. | AbbVie Inc.’s adjusted debt-to-equity improved from 2015 to 2016 and from 2016 to 2017. |
Adjusted ROA | A profitability ratio calculated as net income divided by adjusted total assets. | AbbVie Inc.’s adjusted ROA deteriorated from 2015 to 2016 and from 2016 to 2017. |
Adjusted interest coverage | A solvency ratio calculated as adjusted EBIT divided by adjusted interest payments. | AbbVie Inc.’s adjusted interest coverage deteriorated from 2015 to 2016 and from 2016 to 2017. |
AbbVie Inc., Ratios: Reported vs. Adjusted
Adjusted Total Asset Turnover
Based on: 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-20), 10-K (filing date: 2014-02-21).
2017 Calculations
1 Total asset turnover = Net revenues ÷ Total assets
= ÷
=
2 Adjusted total asset turnover = Net revenues ÷ Adjusted total assets
= ÷
=
Ratio | Description | The company |
---|---|---|
Adjusted total asset turnover | An activity ratio calculated as total revenue divided by adjusted total assets. | AbbVie Inc.’s adjusted total asset turnover deteriorated from 2015 to 2016 but then slightly improved from 2016 to 2017. |
Adjusted Debt to Equity
Based on: 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-20), 10-K (filing date: 2014-02-21).
2017 Calculations
1 Debt to equity = Total debt ÷ Stockholders’ equity
= ÷
=
2 Adjusted debt to equity = Adjusted total debt ÷ Stockholders’ equity
= ÷
=
Ratio | Description | The company |
---|---|---|
Adjusted debt-to-equity | A solvency ratio calculated as adjusted total debt divided by total shareholders’ equity. | AbbVie Inc.’s adjusted debt-to-equity improved from 2015 to 2016 and from 2016 to 2017. |
Adjusted Return on Assets (ROA)
Based on: 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-20), 10-K (filing date: 2014-02-21).
2017 Calculations
1 ROA = 100 × Net earnings ÷ Total assets
= 100 × ÷
=
2 Adjusted ROA = 100 × Net earnings ÷ Adjusted total assets
= 100 × ÷
=
Ratio | Description | The company |
---|---|---|
Adjusted ROA | A profitability ratio calculated as net income divided by adjusted total assets. | AbbVie Inc.’s adjusted ROA deteriorated from 2015 to 2016 and from 2016 to 2017. |
Adjusted Interest Coverage
Based on: 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-20), 10-K (filing date: 2014-02-21).
2017 Calculations
2 Interest coverage = EBIT ÷ Interest expense
= ÷
=
3 Adjusted interest coverage = Adjusted EBIT ÷ Adjusted interest expense
= ÷
=
Ratio | Description | The company |
---|---|---|
Adjusted interest coverage ratio | A solvency ratio calculated as adjusted EBIT divided by adjusted interest payments. | AbbVie Inc.’s adjusted interest coverage ratio deteriorated from 2015 to 2016 and from 2016 to 2017. |
Estimation of Depreciation Expense, Operating Leased Assets
USD $ in millions
Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | ||
---|---|---|---|---|---|---|
Lease expense | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Less: Estimated interest expense, operating lease obligations1 | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Estimated depreciation expense, operating leased assets | ![]() |
![]() |
![]() |
![]() |
![]() |
Based on: 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-20), 10-K (filing date: 2014-02-21).
Estimation of Interest Expense, Operating Lease Obligations
Based on: 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-20), 10-K (filing date: 2014-02-21).
2 Weighted-average interest rate for AbbVie Inc.’s debt
2017 Calculations
3 Estimated interest expense, operating lease obligations = Operating leased assets, at beginning of year × Discount rate
= ×
=
Present Value of Operating Lease Payments, at Beginning of Year
Based on: 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-20), 10-K (filing date: 2014-02-21).
1 Equal to total present value of future operating lease payments. See Details »
2 Weighted-average interest rate for AbbVie Inc.’s debt
2017 Calculations
3 Total present value of operating lease payments, at beginning of year = (Total present value of future operating lease payments + Lease expense) ÷ (1 + Discount rate)
= ( +
) ÷ (1 +
) =